Fingerprint
Navegar pels temes de recerca de 'Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study'. Junts formen un fingerprint únic.- Ordenar per
- Ponderació
- Alfabèticament
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj, David K. B. Li, Hans-Peter Hartung, Bernhard Hemmer, Ludwig Kappos, Mark S. Freedman, Olaf Stueve, Peter Rieckmann, Xavier Montalban, Tjalf Ziemssen, Lixin Zhang Auberson, Harald Pohlmann, Francois Mercier, Frank Dahlke, Erik Wallstroem
- Medical University of Lodz
- University of British Columbia (UBC)
- Heinrich Heine University Düsseldorf
- Technical University of Munich (TUM)
- Universität Basel
- University of Ottawa
- UNIV TEXAS, University of Texas System, UTMD Anderson Cancer Center
- Department of Veterans Affairs
- Dept Neurol Neuroimmunol
- Clin Neuroimmunol Unit
- Technische Universität Dresden
- Novartis Pharma AG
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts
217
Cites
(Scopus)